REGENXBIO founding CEO Ken Mills reviews the company’s recent positive Phase I results for RGX-314, a potentially game-changing gene therapy for wet AMD. Mills also shares the responsibility he feels leading a pioneer in the blockbuster gene therapy field.
Meet Our Host
Joining the company in 2014, to create and manage a new line of podcasts, publications and other editorial products.
STAY UP TO DATE WITH OIS
Get the Latest News, Podcasts and Videos.